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Abstract. 
 
In light chain (LC) amyloidosis an immuno-
globulin LC assembles into ﬁbrils that are deposited in
various tissues. Little is known about how these ﬁbrils
form in vivo. We previously showed that a known amy-
loidogenic LC, SMA, can give rise to amyloid ﬁbrils in
 
vitro when a segment of one of its 
 
b
 
 sheets undergoes a
conformational change, exposing an Hsp70 binding site.
To examine SMA aggregation in vivo, we expressed it
and its wild-type counterpart, LEN, in COS cells. While
LEN is rapidly oxidized and subsequently secreted, newly
synthesized SMA remains in the reduced state. Most
SMA molecules are dislocated out of the ER into the cy-
tosol, where they are ubiquitinylated and degraded by
proteasomes. A parallel pathway for molecules that are
not degraded is condensation into perinuclear aggre-
somes that are surrounded by vimentin-containing inter-
mediate ﬁlaments and are dependent upon intact mi-
crotubules. Inhibition of proteasome activity shifts the
balance toward aggresome formation. Intracellular ag-
gregation is decreased and targeting to proteasomes im-
proved by overexpression of the cytosolic chaperone
Hsp70. Importantly, transduction into the cell of an
Hsp70 target peptide, derived from the LC sequence, also
reduces aggresome formation and increases SMA degra-
dation. These results demonstrate that an amyloidogenic
LC can aggregate intracellularly despite the common pre-
sentation of extracellular aggregates, and that a similar
molecular surface mediates both in vitro ﬁbril formation
and in vivo aggregation. Furthermore, rationally designed
peptides can be used to suppress this aggregation and
may provide a feasible therapeutic approach.
Key words: amyloidosis • BiP • ﬁbril assembly • im-
munoglobulin • proteasome
 
Introduction
 
Amyloidosis is a family of diseases characterized by the as-
sembly of a particular protein into fibrils that are deposited
in various organs and tissues, often resulting in organ failure
and death. Each type of amyloidosis is defined by the con-
stituent protein, and 
 
.
 
20 different proteins are known to be
able to polymerize into fibrils (Westermark et al., 1999).
This group of proteins does not share a common native
structure. Rather, they have in common the ability to un-
dergo a conformational change into a partially folded inter-
mediate that is capable of ordered assembly. The molecular
mechanisms governing this transition have been studied pri-
marily in vitro and only few studies have related the in vitro
findings to cell physiology and pathological manifestations.
Of the many proteins known to aggregate in fibrillar
form, immunoglobulin light chains (LCs),
 
1
 
 the causative
agents of light chain amyloidosis, are unique: they are de-
signed to be highly polymorphic as a way of maximizing
the diversity of the immune repertoire. By contrast, many
other amyloidogenic proteins contain specific, often heri-
table mutations that explain their increased tendency to
shift from the native state to a fibrillogenic form (Perutz,
1994; Zoghbi and Orr, 1995; Kelly et al., 1997). Immuno-
globulin LCs are encoded by multiple gene segments that
rearrange in combinatorial fashion, and the variable do-
main (V
 
L
 
) gene segments also undergo somatic hypermu-
tation. As an inevitable consequence of this sequence
diversification, LCs are produced that are inherently un-
stable and prone to form fibrils. In fact, as little as one or
two amino acid substitutions have been found to suffice
for the in vitro conversion of a soluble LC to an amy-
loidogenic variant (Raffen et al., 1999; Davis et al., 2000).
Typically, LC amyloid deposits are extracellular, and
only rarely do patients present with intracellular LC aggre-
gates (Kjeldsberg et al., 1977; Ishihara et al., 1991). This ob-
servation is puzzling from a biological perspective because
proteins with altered conformations or unassembled sub-
units of oligomeric proteins usually do not transit from the
ER to the Golgi. Rather, they are retained in the ER (Bole
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Abbreviations used in this paper:
 
 ALLN, 
 
N
 
-Acetyl-Leu-Leu-Norleu-
Al; CFTR, cystic fibrosis transmembrane conductance regulator; HA, he-
magglutinin; LC, light chain; SGK, serum and glucocorticoid-inducible ki-
nase; V
 
L
 
, variable domain of light chain. 
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et al., 1986; Gething et al., 1986), dislocated to the cytosol,
and targeted for degradation by proteasomes (Werner et
al., 1996). LC mutants that fit this pattern have been de-
scribed (Ma et al., 1990; Gardner et al., 1993). A second
coping mechanism that was recently reported involves the
extraction of misfolded integral membrane proteins from
the ER membrane, followed by their aggregation into a
perinuclear inclusion body (Johnston et al., 1998). With ei-
ther mechanism, the question remains how an unstable mu-
tant LC might escape the cellular quality control system,
reach the extracellular space, and form fibrils.
Certain LC families, such as 
 
k
 
4 and 
 
l
 
6, have been shown
to be overrepresented in LC deposits (Solomon et al., 1982;
Denoroy et al., 1994; Stevens and Argon, 1999). Earlier work
from our laboratories has focused on the in vitro fiber-form-
ing capability of two members of the 
 
k
 
4 family, LEN and
SMA. LEN differs from the germline sequence by only one
somatic mutation, and was isolated as a Bence Jones protein
from a patient with no evidence of amyloid deposits (Wilkins
Stevens et al., 1995). SMA has eight amino acid substitutions
relative to LEN and was isolated from a patient with LC
amyloidosis (Wilkins Stevens et al., 1995). In vitro, LEN is a
thermodynamically stable protein. SMA, however, is less
thermodynamically stable than LEN (Raffen et al., 1999).
Furthermore, we have shown that the purified, recombinant
V
 
L 
 
of SMA forms fibers upon incubation with shaking at
37
 
8
 
C (Raffen et al., 1999; Davis et al., 2000). These results
support the hypothesis that a conformational change in the
protein is a prerequisite for fiber formation.
Based on our in vitro studies, we have proposed a mo-
lecular model for LC fiber assembly (Davis et al., 2000).
The identification of a V
 
L
 
-derived peptide that prevents fi-
ber formation suggested that an intermolecular loop-
swapping event is important for fiber growth. The peptide
is hypothesized to serve as a competitive inhibitor of fiber
formation by binding to a crevice in the V
 
L
 
 vacated by a
mobile loop containing the peptide. The physiological rel-
evance of these in vitro experiments is currently unknown.
To begin to address these questions in vivo, we have ex-
pressed the complete LC of SMA or LEN in COS cells and
examined their fates. Our data show that an amyloidogenic
protein can aggregate intracellularly. We find that, unlike
LEN, SMA is slow to fold and is readily recognized as an un-
stable protein. It is dislocated into the cytosol, where it either
aggregates into inclusion bodies or is degraded by protea-
somes. The chaperone Hsp70 interacts with SMA in the cy-
tosol and plays an important role in its fate. Overexpression
of Hsp70 improves the solubility of SMA and decreases its
aggregation. Furthermore, we find that the same molecular
surface required for fibril formation in vitro is important for
aggregation in vivo. The same Hsp70-binding peptide that
we showed to inhibit fibril assembly in vitro prevents aggre-
gation of SMA in cells. This ability to modulate the degree of
intracellular LC aggregation with chaperones and peptides
suggests that rationally designed peptides may provide effec-
tive treatment modalities for a variety of amyloidoses.
 
Materials and Methods
 
Plasmids
 
Constructs directing expression of the complete SMA and LEN LC, wild-
type BiP and T19G BiP have been described elsewhere (Davis et al.,
2000). An Hsp70 expression plasmid was constructed by PCR amplifica-
tion of the inducible gene from the pETWThsp70 vector (Abravaya et al.,
1992), a gift of Dr. R. Morimoto (Northwestern University, Evanston, IL).
Amplified material was inserted into the vector pcDNA3.1 (Invitrogen).
An epitope-tagged derivative of this plasmid was generated by an in-
frame insertion of the hemagglutinin (HA) peptide sequence (YPYDYP-
DYA) at the NH
 
2
 
 terminus of Hsp70. An expression plasmid encoding
HA-tagged serum and glucocorticoid-inducible kinase (SGK) was a gift of
Dr. Suzanne Conzen (The University of Chicago).
 
Transfections
 
COS-1 cells were transiently transfected with FuGENE 6 transfection re-
agent (Roche Molecular Biochemicals) according to manufacturer’s in-
structions, and analyzed 2 d later. Overnight incubations with various con-
centrations of 
 
N
 
-Acetyl-Leu-Leu-Norleu-Al (ALLN; Sigma-Aldrich), 10
 
m
 
M lactacystin (Calbiochem), 10 
 
m
 
g/ml nocodazole (Sigma-Aldrich), or
various concentrations of peptides (University of Chicago Peptide Synthe-
sis Facility) were begun the day after transfection.
 
Metabolic Labeling and Immunoprecipitation
 
Culture, metabolic labeling, lysis, and immunoprecipitation of COS-1 cells
were performed as previously described (Dul et al., 1992). Eluates from
equal cell equivalents were resolved on 11% reducing SDS-PAGE gels.
The following antibodies were used in immunoprecipitations: rabbit anti–
human kappa light chain (Bethyl Labs), goat anti–human kappa light
chain (Caltag), and mouse anti–ubiquitin (StressGen).
 
Immunoblotting
 
Cells were transfected in six-well dishes and lysed in the wells with 200 
 
m
 
l
each of the following buffer (mM): 50 Tris-HCl, pH 8.0, 150 NaCl, 5 KCl,
5 MgCl
 
2
 
, 0.5% Triton X-100, 0.5% deoxycholate, and 20 NEM, supple-
mented with protease inhibitors (1 
 
m
 
g/ml each of leupeptin and pepstatin
A; 10 
 
m
 
g/ml each of TLCK, TPCK, and soybean trypsin inhibitor). The ly-
sates were passed through a 25-gauge needle 10
 
3
 
 on ice. Insoluble mate-
rial was recovered by centrifugation at 16,000 
 
g
 
 for 15 min. Pellets were
solubilized in 50 
 
m
 
l 60 mM Tris-HCl, pH 6.8, 5% SDS, 10% glycerol with 1
min of sonication in a cuphold sonicator, followed by 10 min of boiling.
Unless otherwise noted, equal cell equivalents from all samples were sep-
arated on 11% reducing SDS-PAGE gels and transferred to nitrocellu-
lose. Membranes were incubated with goat anti–human kappa light chain
(BioSource) and HRP-conjugated donkey anti–goat IgG (Santa Cruz Bio-
technology), rabbit anti–VSV G (J. Burkhardt, University of Chicago)
and HRP-conjugated goat anti–rabbit IgG (Jackson ImmunoResearch
Laboratories), mouse anti–raf (Transduction Labs) or mouse anti–HA
(Roche Molecular Biochemicals) and HRP-conjugated goat anti–mouse
IgG (Jackson ImmunoResearch Laboratories). Bound antibodies were
detected with SuperSignal West Pico Chemiluminescent Substrate (Pierce
Chemical Co.). Blots were quantitated using scanning densitometry and
NIH Image 1.6 software.
 
Fluorescence Microscopy
 
Cells grown on coverslips were transfected as described above, fixed in
3.7% formaldehyde/PBS, permeabilized, and stained as previously de-
scribed (Burkhardt et al., 1993). The following antibodies were used:
FITC-conjugated goat anti–human kappa light chain (BioSource), mouse
anti–vimentin (Clone V9; Sigma-Aldrich), and Texas red–conjugated rab-
bit anti–mouse IgG (Jackson ImmunoResearch Laboratories).
 
Electron Microscopy
 
Cells were fixed with 1.6% paraformaldehyde/2.5% glutaraldehyde, dehy-
drated, and embedded according to standard procedure. After specimen
preparation, ultrathin sections (60–80 nm) were cut using a Reichert FC-D
ultramicrotome, and picked up on uncoated, 300 mesh, Cu-Rh grids. Sec-
tions were stained for 8 min with 1.5% uranyl acetate and counter stained
for 10 min with lead citrate. Grids were viewed with a JEOL 100CX-II
electron microscope, operated at 80 kV.
 
Synthesis and Treatment of Cells with TAT
Fusion Peptides
 
Peptides were synthesized at the University of Chicago peptide synthesis
facility. An 11-mer sequence (YGRKKRRQRRR) from the HIV TAT 
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protein has been shown to transduce peptides and proteins into cells in a
receptor-independent fashion (Schwarze et al., 1999). A peptide was syn-
thesized that fused this TAT sequence with the V
 
L
 
-derived sequence we
have shown to inhibit fiber formation in vitro (Davis et al., 2000). To en-
sure adequate flexibility and solubility, additional V
 
L
 
 sequence was added
on both sides of the active 7-mer, generating the following sequence for the
TAT-TISS peptide: NH
 
2
 
-YGRKKRRQRRRSGSGTDFTLTISSLQAED-
OH. A control peptide was synthesized (TAT-PASS) in which the criti-
cal hydrophobic residues were substituted with alanines and the ex-
tended structure of the peptide destroyed by the addition of a proline
(NH
 
2
 
-YGRKKRRQRRRSGSGTDATAPASSLQAED-OH). Cells were
treated with either peptide 24 h after transfection and incubated overnight
in the presence of the indicated concentrations of ALLN. Cells were then
harvested for Western blotting or immunofluorescence as described above.
 
Results
 
SMA Is a Nonsecreted Light Chain that Is Degraded
by Proteasomes
 
Unlike most subunits of oligomeric proteins, LCs are secre-
tion-competent even when expressed alone (Shapiro et al.,
1966; Mosmann and Williamson, 1980). As with all proteins,
however, they must be correctly folded to exit the ER and
transit the secretory pathway (reviewed by Gething and
Sambrook, 1992). Thus, secretability is a direct measure of a
LCs ability to fold into the native state. Since LEN was iso-
lated as a Bence Jones protein from the urine of a patient, it
follows that it should be secretion competent, but it is not
known whether the amyloidogenic SMA was secreted, and
then aggregated in the extracellular space. For the purpose
of expressing SMA and LEN in vivo, expression plasmids
were constructed that direct the synthesis of complete
kappa chains, containing either of these two variable region
sequences followed by the constant region of human C
 
k
 
(Hieter et al., 1980). Pulse-chase analysis of COS cells tran-
siently expressing these 
 
k
 
 chains revealed that LEN was se-
creted as a wild-type LC, but that SMA was not secreted
(Fig. 1). Furthermore, SMA was immunoprecipitated from
the cell lysates only immediately after the pulse, and disap-
peared rapidly during the chase. This suggested that SMA
was recognized as a mutant LC by the cellular quality con-
trol system, and was either rapidly degraded and/or aggre-
gated into a detergent insoluble fraction.
Degradation of ER proteins is primarily controlled by
the ERAD system (reviewed by Brodsky and McCracken,
1999). Such proteins are exported to the cytosol, where
they are tagged with polyubiquitin and directed to protea-
somes for degradation. To determine whether SMA under-
goes ERAD-mediated degradation, we treated transfected
cells with the proteasome inhibitors ALLN (Fig. 2) or lac-
tacystin (data not shown) and analyzed the detergent solu-
ble and insoluble fractions by immunoblotting. In un-
treated cells, very little SMA was detected in either
fraction (Fig. 2 A), again consistent with rapid degrada-
tion. Overnight incubation with proteasome inhibitors dra-
matically increased the yield of SMA, the majority of
which was recovered in the detergent-insoluble pellet.
Figure 1. SMA is not secretion competent. COS cells were trans-
fected with expression plasmids encoding either LEN or SMA
human kappa chains. 2 d later, cells were pulse-labeled with 35S-
methionine for 30 min (P) and chased for 1 or 2 h (1 and 2). Intra-
cellular LCs (INT) were immunoprecipitated from the detergent
soluble lysates; secreted LCs (EXT) from the cell culture media.
The eluates were separated on reducing SDS-PAGE. LEN is se-
creted. SMA is recovered only from the pulse lysate sample and
is not secreted.
Figure 2. Proteasome inhibitors increase steady state levels of
SMA, most of which is found in insoluble aggregates. (A) Trans-
fected cells expressing SMA, LEN, or VSV G proteins were incu-
bated overnight in the absence (2) or presence (1) of 10 mg/ml
ALLN. Detergent soluble (S) and pelleted, insoluble (P) frac-
tions were prepared and analyzed by Western blotting with anti–
kappa antibody. The SMA fractions were loaded equally; two
times more insoluble material was loaded for LEN and VSV G.
Insoluble SMA, but not LEN or VSV G, accumulates in the pres-
ence of ALLN. (B) Upon long exposure, a ladder of bands is vis-
ible in the insoluble fraction, reflecting post-translational modifi-
cation of SMA. (C) After overnight incubation with 10 mg/ml
ALLN, soluble (S) and insoluble (P) fractions from SMA (lanes 1
and 2) or mock-transfected (3 and 4) cells were immunoprecipi-
tated with anti–ubiquitin antibody. Precipitated material was an-
alyzed by Western blotting with anti–kappa antibody. For com-
parison, total insoluble lysate (lane 5) was also analyzed by
Western blotting with anti–kappa antibody. The major, 29-kD
band in 1–4 is the light chain from the immunoprecipitating anti-
body; the 29-kD band in 5 is the monomeric, unmodified form of
SMA. (D) After overnight incubation with 10 mg/ml ALLN, in-
soluble fractions from SMA- or mock-transfected cells were im-
munoprecipitated with anti–kappa antibody. Precipitated mate-
rial was analyzed by Western blotting with anti–ubiquitin
antibody. Ubiquitinated forms of kappa are detected only in the
insoluble fraction from SMA-expressing cells. 
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LEN and VSV G protein (an unrelated protein that also
transits through the secretory pathway) were found prima-
rily in the soluble fractions, with only a small quantity be-
coming insoluble in the presence of ALLN. Long expo-
sures of the blots showed that a small proportion of the
insoluble pool consisted of a ladder of higher molecular
weight forms of SMA, indicative of a post-translational
modification (Fig. 2 B). The spacing of these bands was
consistent with progressive addition of ubiquitin to SMA,
which is known to target proteins to the ERAD pathway.
To test this possibility, soluble and insoluble fractions were
immunoprecipitated with anti–ubiquitin antibody, and
then blotted with anti–kappa (Fig. 2 C) or, conversely, im-
munoprecipitated with anti–kappa and blotted with anti–
ubiquitin (D). In the anti–ubiquitin immunoprecipitates,
insoluble SMA was detected in a high molecular weight
smear, as well as in a ladder whose spacing was equivalent
to that seen in the total insoluble fraction of the lysate (Fig.
2 C, compare lane 2 with 5). When anti–kappa immuno-
precipitates were blotted with anti–ubiquitin, a similar high
molecular weight smear was observed, while the smaller
molecular weight ladder was no longer evident. Thus, the
detergent-insoluble fraction contains three pools of SMA
molecules: the majority are unmodified monomers, a sec-
ond pool is polyubiquitinylated, high molecular weight
SMA, and the third pool appears as a regularly spaced lad-
der that is either ubiquitinylated or modified by an alterna-
tive mechanism. Taken together, these experiments dem-
onstrate that SMA molecules are ubiquitinylated and
targeted to proteasomal degradation. However, when the
degradative machinery cannot keep pace with its synthesis,
SMA forms detergent-insoluble aggregates.
 
SMA and Insoluble LEN Remain Permanently Reduced
 
The SMA and LEN proteins differ by only eight amino ac-
ids (Wilkins Stevens et al., 1995), but are processed in vivo
along vastly different pathways. Therefore, we asked
whether a difference in folding between SMA and LEN
could be detected. In reducing gels, LCs migrate as one
band lacking both disulfide bonds (F
 
0
 
). Under nonreduc-
ing conditions, two additional forms of LC are distinguish-
able: a folding intermediate that contains one disulfide
(F
 
1
 
) and the completely oxidized form (F
 
ox
 
) (Hendershot
et al., 1996). With other wild-type LCs, the F
 
0
 
 and F
 
1
 
 forms
are only visible after short pulse labeling and lysis in the
presence of alkylating agents (Melnick et al., 1994; Aviel,
S., J. Melnick, T. Gidalevitz, F.J. Stevens, J.L. Dul, and Y.
Argon, submitted for publication), indicating that these in-
termediates are usually short lived. F
 
ox
 
 is the only LC form
that is secreted from cells, and hence represents the fully
folded, native state.
To examine the folding of SMA and LEN, soluble and
insoluble fractions from ALLN-treated cells were resolved
by SDS-PAGE and analyzed by Western blotting (Fig. 3).
All SMA molecules, whether in the detergent soluble or
insoluble fractions, were found to be in the F
 
0
 
 form. There
was no detectable F
 
1
 
 (which migrates between F
 
0 
 
and F
 
ox
 
)
or F
 
ox
 
 since the migration of SMA was similar under both
non-reducing and reducing conditions. Identical patterns
were obtained with cells that were not treated with protea-
some inhibitors (data not shown). This indicates that SMA
has an early and profound block in folding, failing to oxi-
dize either of its two domains. In contrast to SMA, the mi-
gration of LEN was consistent with the majority of the
molecules having progressed to the completely oxidized,
more compact form (Fig. 3). Only a small fraction of solu-
ble LEN remained in the unfolded, F
 
0
 
 form. However, all
LEN molecules found in the detergent-insoluble fraction
were reduced, indicating that unfolded molecules had been
segregated from those that were correctly folded. Thus,
SMA is an early folding mutant that fails to oxidize even its
constant domain, despite the fact that all its somatic muta-
tions are in the variable domain. This phenotype is un-
usual, as the effects of previously described mutations in
the variable domain seem to be limited to the folding of
only this domain (Hendershot et al., 1996; Skowronek et
al., 1998; Aviel, S., J. Melnick, T. Gidalevitz, F.J. Stevens,
J.L. Dul, and Y. Argon, submitted for publication).
 
SMA Accumulates in Aggresomes
 
Commonly, mutations in secretory proteins prevent exit
from the ER such that the proteins accumulate in that or-
ganelle (Hammond and Helenius, 1995). We previously
determined that the intracellular localization of SMA did
not fit this pattern (Davis et al., 2000). Rather, as shown
again in Fig. 4, it displayed features that were unique.
First, there was some ER staining, but it was frequently
obscured by diffuse cytoplasmic staining. Second, in most
cells, anti–kappa staining was prevalent throughout the
nucleus, but the nucleoli were negative. Third, roughly one
third to one half of SMA-expressing cells exhibited con-
centrated perinuclear staining that at first appeared simi-
lar to the Golgi staining observed in LEN-expressing cells
(Fig. 4, A and B). However, we have determined, through
a series of experiments described in detail below, that
these structures were instead perinuclear inclusions. Only
one such SMA-induced perinuclear inclusion body was
observed in each cell, and the frequency of cells with these
inclusions was increased substantially when proteasomal
activity was inhibited (see Figs. 6 and 8).
Similar structures, termed aggresomes, were observed in
cells where the degradation of cystic fibrosis transmem-
brane conductance regulator (CFTR) was blocked. These
Figure 3. SMA and insoluble LEN do not progress in folding.
Transfected cells were treated with 10 mg/ml ALLN overnight.
Soluble (S) and pelleted, insoluble (P) fractions were separated
by SDS-PAGE under reducing (R) and nonreducing (NR) condi-
tions and analyzed by Western blotting. Twofold more insoluble
than soluble material was loaded. F0, completely reduced LC; Fox,
LC containing two disulfide bonds. Only soluble LEN folds into
the Fox state. All of SMA, insoluble LEN, and a small percentage
of soluble LEN is found in the F0 state. 
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aggresomes were shown to be surrounded by vimentin fila-
ments and to require intact microtubules to form (Johnston
et al., 1998). To further characterize the SMA-induced in-
clusion bodies, transfected cells were double labeled with
anti–kappa and –vimentin antibodies. In LEN-expressing
cells, the vimentin filaments formed a dense, filamentous
network that extended to the periphery of the cells (Fig. 4
C). In cells expressing SMA, the vimentin distribution was
quite different, having collapsed into a perinuclear location
coincident with the inclusion body. This collapse of the vi-
mentin filaments was observed in cells overexpressing SMA
regardless of ALLN treatment, although the presence of
the drug intensified the effect (Fig. 4, D and E).
Treatment of SMA-expressing cells with nocodazole
completely abrogated inclusion body formation (Fig. 4 F).
Instead, multiple smaller aggregates were found dispersed
throughout the cytosol. In contrast to the ALLN-induced
aggresomes of CFTR (Johnston et al., 1998), even pre-exist-
ing SMA aggresomes were disrupted and dispersed by no-
codazole treatment. Thus, intact microtubules play a critical
role in the generation and maintenance of aggresomes.
Electron microscopy of SMA-expressing cells treated
with ALLN revealed a large area (2–4 
 
m
 
m in diameter)
near the nucleus, containing electron-dense clusters of ma-
terial (Fig. 5 A). The appearance of this area was depen-
dent on SMA expression; neither nontransfected nor
LEN-expressing cells treated with ALLN exhibited this
type of structure. These areas were, for the most part, de-
void of other organelles and were surrounded by interme-
diate filaments (Fig. 5 B). Hence, the inclusions formed by
cells in response to the overexpression of SMA have the
hallmarks of aggresomes (Johnston et al., 1998).
Figure 4. SMA is dislocated
from the ER and accumulates
in vimentin-ringed aggresomes.
Cells transfected with LEN (A
and C) or SMA (B and D–F)
were incubated without (A–D
and F) or with (E) 10 mg/ml
ALLN overnight. Cells were
processed for immunofluores-
cence with anti–human kappa
antibody only (green, A, B, and
F), or double labeled with the
same antibody and anti–vimen-
tin antibody (red, C–E). LEN
shows reticular and Golgi stain-
ing typical of a secreted protein
(A and C); SMA (B, D, and E)
exhibits diffuse staining of the
cytosol and nucleus, plus con-
centrated staining of a perinu-
clear aggresome. In LEN-trans-
fected cells (C), vimentin is
distributed throughout the cyto-
plasm; in SMA-transfected cells
(D and E), the network of fila-
ments collapses, concentrating
around the aggresome. In SMA-
transfected cells treated with no-
codazole (F), the aggresomes
are dispersed. 
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Coexpression of the Cytosolic Chaperone Hsp70 
Inhibits SMA Aggregation
 
Recently, we showed that purified, recombinant Hsp70
blocked fibril formation by recombinant variable domains
in vitro (Davis et al., 2000). BiP, the ER homologue of
Hsp70, also prevented in vitro fibril formation, but was
less efficient than Hsp70. Moreover, BiP suppressed ag-
gregation in vivo. In particular, a mutant BiP that is unable
to release substrate (T19G BiP) caused a larger pool of
SMA to be retained within the ER and decreased the
frequency of aggresome formation (Davis et al., 2000).
Figure 5. Ultrastructure of ag-
gresomes. SMA-transfected
cells were treated overnight
with 10 mg/ml ALLN and pro-
cessed for electron micros-
copy. (A) A low magnification
view showing a cell with a
perinuclear zone excluding
other organelles and contain-
ing electron-dense clusters of
material (arrows). N, nucleus.
Bar, 4 mm. (B) High magnifi-
cation view showing an aggre-
some composed of aggregated
protein (electron dense mate-
rial, white stars) surrounded
by filamentous structures (ar-
rowheads), consistent with vi-
mentin intermediate fila-
ments. Bar, 0.5 mm.
Figure 6. Hsp70 promotes SMA solu-
bility and degradation. Cells transfected
with SMA alone (open bars) or cotrans-
fected with Hsp70 (filled bars) were in-
cubated overnight in the absence (2) or
presence (1) of 10 mg/ml ALLN and
processed for immunofluorescence with
anti–kappa antibody. SMA-expressing
cells were scored for the presence of ag-
gresomes (n  5 100 cells counted for
each condition). (B) Cells were trans-
fected with SMA alone (2), or with
SMA plus one of the following: BiP,
T19G BiP, Hsp70, or VSV G. Soluble
(S) and insoluble (P) fractions were an-
alyzed by Western blotting with anti–
kappa antibody (top). The same blot
was reprobed with anti–raf antibody
(bottom). When coexpressed with
Hsp70, more SMA partitions into the
soluble fraction. (C) Cells were trans-
fected as in B, incubated overnight in
the presence of 10 mg/ml ALLN, and
analyzed as above. Here, two times
more insoluble than soluble material
was loaded. Short exposure shows an increase in soluble SMA expressed with chaperones; Hsp70 co-
expression also leads to a decrease in insoluble SMA (top). Long exposure of the same blot shows
that the insoluble SMA ladder is present when SMA is expressed alone, or with BiP, but not when
Hsp70 is coexpressed with SMA (bottom). (D) Cells transfected with SMA (lane 1), SMA plus Hsp70
(2 and 4), Hsp70 (3), or SMA plus SGK (5) were treated overnight with 10 mg/ml ALLN. They were
metabolically labeled with 35S-methionine for 3 h, also in the presence of ALLN. Soluble fractions
were immunoprecipitated with anti–human kappa antibody and protein-A beads (1–3 and 5) or pro-
tein-A beads alone (4). Hsp70 specifically coprecipitates with SMA when they are coexpressed. (E)
Cells transfected with SMA plus HA-Hsp70 (lanes 1 and 4), SMA plus HA-SGK (2 and 5), or mock
transfected (3 and 6) were treated overnight with 10 mg/ml ALLN. Soluble fractions were immuno-
precipitated with anti–kappa antibody. Soluble lysate (1–3) and precipitated material (4–6) were ana-
lyzed by Western blotting with anti–HA antibody. Only HA-Hsp 70 coprecipitates with SMA. 
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Therefore, we asked whether coexpression of Hsp70 with
SMA would decrease the frequency of aggresome forma-
tion (Fig. 6 A). Without ALLN treatment, 30% of the
COS cells contained aggresomes as assayed by immuno-
fluorescence. Addition of ALLN increased the proportion
to 75%, but coexpression of Hsp70 dramatically decreased
the frequency of aggresomes to 12% whether or not
ALLN was present.
To further investigate the effects of Hsp70 and BiP on
the aggregation of SMA in vivo, we used a biochemical as-
say. The experiments in Fig. 6 demonstrate that forced in-
teraction with these chaperones improves the fate of SMA.
When BiP or T19G BiP were coexpressed with SMA, a
modest effect on the pool size of soluble LC was observed,
as compared with cells transfected with SMA alone. This
effect was variable in the absence (Fig. 6 B, top), but con-
sistently observed in the presence (C, top), of ALLN. How-
ever, coexpression of either of these chaperones had no ef-
fect on the size of the insoluble SMA pool (Fig. 6 C, top).
Overexpression of cytosolic Hsp70, however, had a dra-
matic effect on SMA aggregation, both quantitatively and
qualitatively. The yield of insoluble SMA was reduced
three- to eightfold, while that of soluble SMA was propor-
tionately increased (Fig. 6, B and C, top). In addition,
longer exposure of the same blot showed a decrease in the
insoluble ladder of SMA only when Hsp70 was coex-
pressed (Fig. 6 C, bottom). To demonstrate direct interac-
tion between Hsp70 and SMA, soluble fractions from met-
abolically labeled cells were immunoprecipitated with anti–
kappa antibody and analyzed with reducing SDS-PAGE
(Fig. 6 D). In cells cotransfected with Hsp70 and SMA, a
70-kD band was specifically coimmunoprecipitated with
SMA (Fig. 6 D, lane 2). By contrast, overexpression of an
irrelevant cytosolic protein, SGK, did not result in copre-
cipitation of that protein with SMA (lane 5). To verify that
the coprecipitating band was indeed Hsp70, Western blot-
ting was performed on anti–kappa immunoprecipitates
from cotransfected cells (Fig. 6 E). The HA-tagged Hsp70
was detected by anti–HA antibody only in soluble lysates
(Fig. 6 E, lane 1), and anti–kappa precipitates (lane 4) from
cells cotransfected with SMA and HA-Hsp70. The HA-
tagged SGK, although present in the lysate, was not found
in the precipitated samples (compare lane 2 with 5). We
conclude that Hsp70 interacts directly with SMA in the cy-
tosol to decrease aggregation and aggresome formation,
and improve targeting for degradation by the proteasome.
Together with our previous work (Davis et al., 2000),
these experiments show that the fate of misfolded, amy-
loidogenic LC was altered by increased interactions with
Hsp70 family chaperones on either side of the ER mem-
brane: more SMA was retained in the ER, less was aggre-
gated, and more of it remained in a soluble state, whether
in the lumen of the ER or in the cytosol. Since the majority
of SMA at steady state is in the dislocated, cytosolic pool,
Figure 7. A VL-derived pep-
tide inhibits SMA aggrega-
tion in the cell. (A) Sche-
matic representation of VL
(numbers indicate amino
acid residues; CDR1-3 indi-
cates the portions of the se-
quence that contribute to the
antigen-binding site), includ-
ing the location and sequence
of the BiP- and Hsp70-bind-
ing peptide (TISS). This pep-
tide was synthesized as a fu-
sion with the HIV-derived
11-mer TAT peptide to per-
mit diffusion across all cell
membranes. A control pep-
tide that does not bind BiP
(PASS), because of four sub-
stitutions, was also fused to
TAT in similar fashion. (B)
SMA-transfected cells were
incubated overnight in the
presence of the indicated
concentrations of ALLN and
50 mM peptide, as indicated.
Equal cell equivalents from
the soluble fractions were
loaded on an SDS gel and analyzed by Western blotting with anti–kappa antibody (top). N, no peptide added; T, TAT-TISS peptide
added; P, TAT-PASS peptide added. Steady state levels of SMA are decreased in the presence of TAT-TISS peptide. The same blot was
reprobed with anti–raf antibody (bottom). (C) Quantification of SMA in the soluble and insoluble fractions. SMA-transfected cells were
incubated overnight in the presence of 10 mg/ml ALLN plus the indicated concentrations of either the Hsp70-binding peptide (TISS) or
the control peptide (PASS). Soluble (unfilled bars) and insoluble (filled bars) fractions were analyzed by Western blotting with anti–
kappa antibody and quantified. Note the loss of SMA with increasing TISS peptide concentration, particularly from the detergent-insol-
uble fractions. (D) Long exposure of a blot prepared as in C, but with twofold more insoluble than soluble material loaded, shows that
with increasing TISS peptide there is a diminution of the ladder of SMA molecules. 
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BiP would be expected to have less of an effect than
Hsp70 when the total cellular protein is analyzed, and this
is indeed what we observed.
 
An Hsp70-binding Peptide Derived from the LC 
Sequence Inhibits SMA Aggregation In Vivo
 
The activity of Hsp70 family proteins in the in vitro fiber-
forming assay is due to their peptide-binding activity, be-
cause inclusion of a specific, V
 
L
 
-derived BiP- and Hsp70-
binding peptide, FTLTISS (amino acids 71–77), blocked
the polymerization of SMA fibrils (Davis et al., 1999,
2000). Therefore, we asked whether this peptide also in-
hibits SMA aggregation in vivo (Fig. 7). To optimize deliv-
ery of the peptide to all cellular compartments, it was syn-
thesized with the 11-mer sequence from the HIV TAT
protein at the NH
 
2
 
 terminus (Gius et al., 1999; Fig. 7 A).
This TAT peptide permits the transduction of denatured
proteins across cell membranes rapidly and efficiently in
an energy- and receptor-independent fashion (Schwarze et
al., 1999). In addition to the test peptide, TAT-TISS, an-
other TAT-fusion was employed as a specificity control.
This peptide, TAT-PASS, contains four amino acid substi-
tutions (Fig. 7 A) and does not inhibit fibril formation in
vitro (Davis et al., 2000). SMA-transfected cells were incu-
bated overnight in the presence of increasing concentra-
tions of ALLN and 50 
 
m
 
M of each peptide (Fig. 7 B). In
the range of 1–10 
 
m
 
g/ml ALLN, there was a progressive in-
crease in the amount of SMA found in the soluble fraction
on a per cell basis (Fig. 7 B, top, N). Inclusion of the TAT-
TISS peptide dramatically reduced the amount of SMA
recovered at all ALLN concentrations tested (Fig. 7 B,
top, T). In contrast, the TAT-PASS peptide had no effect
(Fig. 7 B, top, N and P). Incubation of the same blots with
anti–raf antibody demonstrated that equal cell equivalents
were loaded across the gel (Fig. 7 B, bottom).
We also examined the effect of different concentrations
of peptide on SMA after treatment with 10 
 
m
 
g/ml ALLN.
As shown in Fig. 7, C and D, the TAT-TISS peptide de-
creased the yield of SMA in the insoluble fractions much
more than in the detergent-soluble fractions. The magni-
tude of the decrease was from 4- to 10-fold (
 
n
 
 
 
5 
 
3), in a
peptide concentration-dependent fashion, whereas the
TAT-PASS peptide had only a marginal effect even at the
highest concentration used. As observed with coexpres-
sion of Hsp70, upon addition of the TAT-TISS peptide,
the ladder of SMA was diminished (Fig. 7 D). This indi-
cated that these molecules were being maintained in a sol-
uble form long enough to be kept off the aggregation path-
way and were degraded by the proteasome.
Lastly, we asked whether the decrease in steady state
level of SMA in the presence of TAT-TISS peptide corre-
lated with a decrease in the frequency of aggresome for-
mation, by scoring anti–kappa stained cells (Fig. 8 A).
Roughly 30% of untreated cells exhibited aggresomes, and
this number increased to 
 
z
 
65% upon addition of ALLN
(Fig. 8 B). Transduction of TAT-TISS decreased the num-
ber of aggresomes by more than half, to 25%, about the
same as in untreated cells, whereas addition of TAT-PASS
peptide had no significant effect (Fig. 8 B). Hence, the
large decrease in insoluble SMA observed in the presence
of TAT-TISS peptide coincides with a drop in aggresome
formation.
Figure 8. Inhibition of aggre-
some formation in the presence
of TAT-TISS peptide. Trans-
fected cells were treated over-
night with 10 mg/ml ALLN and
100 mM peptide and processed
for immunofluorescence with
anti–kappa antibody. (A) Repre-
sentative cells are shown for each
treatment. (B) SMA-expressing
cells were scored for the pres-
ence of aggresomes (n 5 80–100
cells counted for each condition). 
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Discussion
 
This study shows that when an amyloidogenic LC fails to
fold properly, it is dislocated out of the ER to the cytosol,
where two linked coping mechanisms come into play.
Much of the LC is targeted for degradation by protea-
somes, but a considerable fraction aggregates intracellu-
larly into one large inclusion body. The two alternative
pathways are linked because inhibition of degradation in-
creases aggregation and, most remarkably, introduction of
a specific peptide into the cell inhibits aggregation and in-
creases the efficiency of LC degradation. Thus, the two
pathways seem to be in a kinetic competition.
Despite the fact that SMA was isolated from an extra-
cellular fibrillar aggregate, it is not secreted and is dis-
posed of quite efficiently. Even when overexpressed, as in
our transient expression system, the majority of SMA mol-
ecules are degraded efficiently, disappearing from the sol-
uble lysate with a half-time of 
 
,
 
1 h. In parallel, a large
fraction of cells exhibit a SMA-containing inclusion body.
As a result of both mechanisms, steady state levels of
SMA are only barely detectable when cells are lysed with
nonionic detergents. Hence, our data show that COS cells
have sufficient quality control capacity to deal with a
heavy load of nonsecreted, highly aggregation-prone pro-
tein. They also show that a soluble secretory protein is dis-
posed of via the same dislocation and proteasomal degra-
dation pathway as misfolded proteins that span the ER
membrane.
The inclusion bodies formed by SMA have the proper-
ties of aggresomes as defined by Johnston et al. (1998). As
shown by both light and electron microscopy, there is usu-
ally only one large, perinuclear inclusion per cell; the ul-
trastructure of the dense material is similar to that of
CFTR-containing aggresomes; the inclusion body does not
appear to be bound by membrane, but does appear to be
ringed by filaments that include microtubules and inter-
mediate filaments (Johnston et al., 1998). The aggresomes
are distinct from Russell bodies, which are intracellular in-
clusion bodies consisting of ER-derived vesicles. Russell
bodies appear when intact Ig is expressed at high levels
and in cells expressing germline heavy chain 
 
m
 
 sequences
(Matthews, 1983; Tarlinton et al., 1992).
Given recent evidence that a large fraction of nascent
chains is never fully folded and is therefore subject to pro-
teasomal degradation (Schubert et al., 2000), it should be
noted that our data show SMA to be efficiently translated
and even translocated into the ER lumen. When degrada-
tion is inhibited, the total amount of full-length SMA is of
the same order of magnitude as that of full-length wild-
type LC, except that much of it is found in a detergent-
insoluble form. Thus, there is no evidence for translational
control mechanisms downregulating SMA expression.
Second, although our polyclonal antibodies recognize mul-
tiple epitopes in the 
 
k
 
 chain, only full-length molecules
were detectable by metabolic labeling or immunoblotting.
Third, the ability to affect the intracellular distribution of
SMA via prolonged interaction with a nonreleasing ver-
sion of BiP (Davis et al., 2000) shows that at least a large
fraction of molecules are translocated into the ER. Almost
all of these molecules, however, never fold properly and
are evidently dislocated into the cytosol for disposal.
The severe folding defect of SMA is rather surprising
and was not predicted from the sequence of the protein;
most of the somatic mutations relative to the germline se-
quence are localized within the antigen-binding loops, and
none are found in the constant domain. Previous work
with a number of murine LC mutants showed that, in gen-
eral, mutations in the variable domain only affect the fold-
ing of this domain while allowing folding of the constant
domain (Hendershot et al., 1996; Skowronek et al., 1998;
Aviel, S., J. Melnick, T. Gidalevitz, F.J. Stevens, J.L. Dul,
and Y. Argon, submitted for publication). The failure of
SMA to oxidize even its constant domain is therefore un-
usual and indicates that V
 
L
 
 and C
 
L
 
 folding is coupled.
Studies are in progress to determine whether this property
is due to the particular sequence of SMA or to differences
between murine and human LC.
Surprisingly, immunofluorescence staining shows that
SMA is also transported into the nucleus, where it is
evenly distributed, although it is excluded from the nucle-
oli (Fig. 4). This pattern is not observed with other mis-
folded proteins that are degraded via the ERAD system.
Active proteasomes have been shown (using GFP label-
ing) to translocate slowly from the cytosol to the nucleus
(Reits et al., 1997). We therefore hypothesize that full-
length SMA, or a large fragment thereof, is associated
with proteasomes for a considerable time before degrada-
tion, and in this way migrates into the nucleus. If so, this
prolonged association may reflect the rate-limiting step in
the degradation pathway and may explain the reason for
the kinetic competition between proteasome degradation
and aggresome formation.
Hsp70 chaperones are instrumental in dictating the fate
of SMA at several levels. First, our data are consistent
with previously published work on the role of BiP in bind-
ing and “selecting” inappropriately folded LC, both in the
lumen of the ER and at the translocon itself (Hamman et
al., 1998; Gething, 1999). BiP binds to LC mainly via its V
 
L
Figure 9. Model of competing pathways of SMA degradation
and aggregation in vivo. Binding to BiP in the ER, or Hsp70 or
TAT-TISS peptide in the cytosol, helps prevent SMA from ag-
gregating. Ubiquitination (Ub) targets soluble SMA for degrada-
tion by proteasomes. ALLN inhibits degradation, thus driving
more SMA into insoluble aggresomes. Dotted line indicates that
a small portion of insoluble SMA is ubiquitinated; otherwise, the
size of the arrows is not meant to indicate efficiency of the step. 
The Journal of Cell Biology, Volume 152, 2001 714
 
domain; this interaction is transient and likely repetitive
(Hendershot et al., 1996; Davis et al., 1999). The presence
of a nonreleasing BiP mutant (or high levels of wild-type
BiP) “traps” SMA molecules in the ER lumen that would
otherwise be quickly dislocated to the cytosol. Second, the
data show that once dislocated, interaction of SMA with
cytosolic Hsp70 (and/or Hsc70) improves the efficiency of
degradation. Overexpression of Hsp70 decreased the in-
soluble pool of SMA that accumulated in the presence of
proteasome inhibitors. In the absence of proteasome in-
hibitors, however, the level of endogenous Hsp70 was suf-
ficient to support degradation of most SMA LCs. This sup-
ports the idea of kinetic competition between degradation
and aggregation: when there is sufficient Hsp70 present to
keep SMA soluble, more of it gets degraded, but if the
level of Hsp70 is inadequate, then more SMA aggregates.
Thus, SMA is a type of proteasomal substrate whose deg-
radation is improved by chaperone interactions, as shown
in vitro with other proteins by Bercovich et al. (1997).
Our data can be incorporated into the following model
(Fig. 9). SMA fails to progress along a productive folding
pathway and hence both its domains remain in the re-
duced state in vivo. The presence of the highly unstable 
 
k
 
4
protein is detected by BiP, presumably during or soon af-
ter its translocation across the ER membrane. Binding to
BiP prevents SMA aggregation in the lumen and facili-
tates its dislocation back to the cytosol. Once there, bind-
ing to Hsp70 (or related chaperones) serves to maintain
SMA in a degradation-competent state so that it can be
ubiquitinated and rapidly targeted to proteasomes. At the
same time, Hsp70 inhibits the tendency of SMA to aggre-
gate in the cytosol, thus regulating the balance between
degradation and aggregation. The inability to fold exposes
(at least) the two major peptides in each of the two 
 
b
 
sheets of the V domain that are good sites for binding of
Hsp70 family chaperones. Continued exposure of these
sites enables associations first with BiP (within the ER),
and then with Hsp70 (in the cytosol). The FTLTISS pep-
tide, which is effective in reducing intracellular aggrega-
tion, has the sequence of one of these two major sites, and,
importantly, the same features that are required for its an-
tiaggregation activity are necessary for its Hsp70 binding
activity (Davis et al., 1999). We envisage the peptide inter-
acting with the same amino acids in the hydrophobic core
of the V domain normally occupied in the folded molecule
by the endogenous FTLTISS peptide. In this way, the pep-
tide acts as a surrogate chaperone, inhibiting aggregation
and promoting degradation. This suggests the possibility
of new treatment modalities using rationally designed pep-
tides to suppress aggregation.
If our data with SMA holds true for other amy-
loidogenic LCs, then how do amyloids form? In our view,
both arms of the cellular quality control system, degrada-
tion and aggresome formation, explain the low frequency
of LC amyloidosis and provide a mechanism for fibrillo-
genesis. Amyloid LCs are always somatically mutated, and
the frequency of destabilizing mutations is much higher
than the frequency of expressed amyloidogenic LCs (Ste-
vens and Argon, 1999). This implies that there is selection
against such mutants. The efficient recognition of unsta-
ble LC by BiP (and possibly other ER molecules), com-
bined with the dislocation and degradation pathways, en-
able a B cell to dispose of the undesired LC and perhaps
to express a new LC, through a process known as “recep-
tor editing” (Gay et al., 1993; Retter and Nemazee, 1998).
Normally, there is sufficient degradative capacity, but
when it is overloaded, aggresomes are formed as a gener-
alized cellular response to the stress of protein aggrega-
tion. We infer from the high fraction of cells that sponta-
neously form aggresomes that mere overexpression of an
amyloidogenic LC is sufficient to induce aggresome for-
mation. The increase in aggresome formation that occurs
when proteasome activity is inhibited further suggests
that there is a balance between the two disposal pathways.
It is not clear whether SMA molecules in the aggresome
are still a viable substrate for degradation (Johnston et al.,
1998). If so, the aggresome may serve as a substrate
“holding station” for proteasomes. Either way, aggre-
somes may be highly relevant for extracellular amyloid
formation, because their induction may lead to cell death,
releasing large quantities of aggregated LC into the extra-
cellular space. When a large clone of cells undergoes such
cell death, sufficient material may be released to initiate
fibrillogenesis.
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